AtriCure Earnings Call - ATRICURE INC

Explicit Guidance:

• Long-Term Financial Targets (2028/2030): Management aims to be a double-digit revenue grower with adjusted EBITDA margins north of 20% by 2028 and 2030. Current performance is pacing ahead of these long-range plan (LRP) targets.
• Gross Margins: Expect to return to gross margins north of 77% in the near term following the transition to a new manufacturing facility; current margins are already exceeding 77%.
• Revenue Growth Composition: Projected growth will continue to be driven primarily by volume rather than price; pricing contribution remains under 2% of total company growth.
• SG&A Leverage: Anticipates continued operating leverage in SG&A as the business scales, allowing for profitable growth even with increased investment.

Business-Segment Outlook:

• Cardiac Surgery (AFib):
  • Encompass Clamp: Continued strong growth expected; US penetration close to 70% with growth driven by existing accounts increasing case frequency rather than new account acquisition.
  • Appendage Management (Clip/Clip): Significant runway for growth remaining in US and international markets (current OUS penetration <30%); expected to accelerate adoption following upcoming clinical trial readouts (BOX and LEAPS).
  • CONVERGE Procedure: Positioned as a robust option for complex, post-failure AFib patients (not first-line); expected to capture patients who have failed multiple catheter ablations.
• Pain Management:
  • CryoNerve Block: Viewed as having "huge" potential beyond thoracic/sternotomy procedures; expansion into amputation (Cryo XT) and Nuss procedure markets where it has achieved >90% penetration.
  • Market Expansion: Expectation of broader surgeon adoption for the Cryo XT device in amputation cases; "no longer a Nuss season," implying year-round demand due to reduced recovery anxiety.
• International Markets: Significant opportunity for growth; penetration rates outside the US are estimated below 30%. Reimbursement challenges exist in OUS markets compared to the US.

Market and Competitive Outlook:

• Competitive Position: Encompass is viewed as the dominant cardiac surgery ablation technology; Medtronic holds a small share. PFA technology is seen as less disruptive in open-heart surgery due to the proven durability and safety of RF in this setting.
• Demand Trends: AFib prevalence rising due to aging population; diagnostics improving. Surgeons increasingly viewing procedures as "easier" and more routine due to technology like Encompass, driving volume.
• Pricing Pressure: Minimal price-based growth; volume wins. Some premium ASP contribution from newer appendage management devices (Flex MiniClip, Pro MiniClip), but volume is the primary driver.

Macro / Industry Outlook:

• Reimbursement: US cardiac surgery reimbursement codes described as "generous" and "generous in cardiac surgery," providing insulation from pressure. Procedures are often attached to emergent surgeries, offering stability against broader ACA or reimbursement reforms.
• Opioid Crisis: Headwinds/opportunities driven by the focus on non-opioid pain management solutions; surgeons prioritizing devices that reduce dependency and pain.
• Cost Inflation: Anticipates "typical inflation" impacting labor costs and supply chain, though supply chain pressures have largely settled.

Strategic Initiatives:

• Clinical Trials: Funding for the BOX and LEAPS trials (appendage management) completed organically without debt; timing aligned with turning point to profitability.
• Manufacturing: New manufacturing facility currently under construction to support "eyes on significant continued growth"; investment expected to be fully amortized before margins normalize above 77%.
• Sales Force Expansion:
  • US: Planning to "right-size" territories in 2027 in anticipation of a PMA (likely for BOX) in 2028 to support potential doubling/tripling of patient volume.
  • Pain Management: Continued hiring of reps; expansion of "therapy development" resources to accelerate adoption in new indications (amputation).
• M&A: Discipline remains high; organic R&D is the primary focus. Appetite for bolt-on acquisitions is "very small" as internal pipeline and investment opportunities are prioritized over integration risks.

Risks and Headwinds to Outlook:

• Clinical Trial Uncertainty: BOX and LEAPS trial outcomes are "unknown and quantum"; success is nebulous and depends on hitting specific clinical endpoints (e.g., 10% absolute differential) to shift guidelines and drive adoption.
• Reimbursement Variance: While US is favorable, international reimbursement is "trickier" with higher resistance on pricing.
• Device Cost Perception: Surgeons may resist adoption in certain procedures due to the "cost of the device" relative to specific reimbursement benefits; adoption varies by surgeon profile (selective vs. broad usage).
• Hiring Environment: Competitive landscape for clinical sales reps who possess deep cardiac surgery knowledge.

Management Tone on the Future:

• Confidence: Describes current position as "enviable," noting the ability to fund large trials, remain profitable, and expand simultaneously.
• Optimism: High confidence in the "long runway" of opportunities across multiple franchises; views the business as a "broad-based" entity with growth in untapped markets.
• Correction of Narrative: Management emphasizes that the market often "obsessively drills into one thing" (e.g., Converge/Clip), underestimating the breadth of the company's growth drivers and the "long runway" in each franchise.

Miscellaneous:

• Timeframe for Market Shift: Anticipates BOX trial success leading to guideline changes and accelerated velocity in appendage management adoption.
• Sales Force Profile: Hiring focus on "clinically oriented" individuals with a passion for cardiac surgery (former PAs, nurses) rather than traditional sales profiles.